Baxiva
Schlieren
About Baxiva
Baxiva is an emerging biotechnology startup focused on the development of next-generation glycoconjugate vaccines designed to prevent and combat bacterial infections. By leveraging advanced glycoengineering technologies and innovative vaccine platforms, Baxiva aims to create more effective and longer-lasting immunizations that address both existing and emerging bacterial threats.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $3.2M
- Last round: Grant (Feb 2026)
- Website: baxiva.com
Industries & Categories
Medical
Social Profiles
Canonical: https://fsome.com/organization/baxiva-131964 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.